Item 7.01 Regulation FD Disclosure

On November 16, 2012, Illumina, Inc. confirmed that it is "Party H" as named in the Schedule 14D-9 (and related amendments) filed by Complete Genomics, Inc. in connection with the tender offer by Beta Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly owned subsidiary of BGI-Shenzhen, a company organized under the laws of the People's Republic of China (together with Purchaser, "BGI"), to purchase all of the outstanding common stock of Complete Genomics. Illumina further confirmed that it submitted proposals to acquire Complete Genomics on the terms disclosed by Complete Genomics in its Schedule 14D-9 (and related amendments). Illumina's most recent proposal, submitted on November 5, 2012, included the following terms:

• a per share cash purchase price of $3.30, which represented approximately a 5% premium over the consideration offered by BGI;

• financed with cash-on-hand; and

• without any condition for further due diligence.

---